LATEST NEWS
-
IRA’s Drug Price Negotiation Program Could Save Medicare $1.8B in First Year
-
Stroke, Clot Risk Halved When Apixaban Taken Versus Rivaroxaban
-
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study.
-
WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
-
GHW International Warns of Sharp Drop in H1 Profit